Geriatrics & gerontology international · 2026
Impact of the Medical Policy Intervention for Polypharmacy on Long-Term Prescriptions of Hypnotic Medications in Older Patients: An Interrupted Time-Series Analysis Using a Nationwide Claims Database in Japan.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kimura Takeshi, Yamamoto Kazuhiro, Saeki Ryunosuke, Omura Tomohiro, Yano Ikuko
Аннотация
OBJECTIVE: This study aimed to evaluate the impact of the medical fee revisions related to polypharmacy in Japan on the long-term hypnotic prescriptions in older patients.
METHODS: We utilized the JMDC medical institution database. Outpatients and inpatients aged ≥ 50 years were included. The target hypnotics included benzodiazepines (BZDs), z-drugs, and ramelteon and orexin receptor antagonists (ramelteon/ORAs). The incidence rates of the newly initiated ≥ 4 weeks of prescriptions per 10 000 outpatients and inpatients (LP-rate) in each month from 2015 to 2022 were calculated. An interrupted time-series analysis was conducted with the intervention point of April 2020 when the medical fees were revised.
RESULTS: The average number of outpatients and inpatients in the database from 2015 to 2022 was 828,510/month. The LP-rates of BZDs and z-drugs gradually decreased from 210 to 125 and 111 to 78.6, respectively, from January 2015 to December 2022, whereas that of ramelteon/ORAs increased from 7.41 to 54.4. In the LP-rate of BZDs and z-drugs, although the level significantly increased by factors of 1.08 [95% confidence interval (CI): 1.02-1.13] and 1.12 [95% CI: 1.08-1.16], respectively, at the intervention time, the slope change significantly decreased after the intervention (0.990 [95% CI: 0.988-0.992] and 0.994 [95% CI: 0.993-0.996]). In ramelteon/ORAs, the slope change with the increasing trend was significantly attenuated after the intervention (0.991 [95% CI: 0.986-0.995]).
CONCLUSIONS: The medical fee revisions related to polypharmacy significantly redirected the long-term prescription trends of BZDs, z-drugs, and ramelteon/ORAs toward a decline.
METHODS: We utilized the JMDC medical institution database. Outpatients and inpatients aged ≥ 50 years were included. The target hypnotics included benzodiazepines (BZDs), z-drugs, and ramelteon and orexin receptor antagonists (ramelteon/ORAs). The incidence rates of the newly initiated ≥ 4 weeks of prescriptions per 10 000 outpatients and inpatients (LP-rate) in each month from 2015 to 2022 were calculated. An interrupted time-series analysis was conducted with the intervention point of April 2020 when the medical fees were revised.
RESULTS: The average number of outpatients and inpatients in the database from 2015 to 2022 was 828,510/month. The LP-rates of BZDs and z-drugs gradually decreased from 210 to 125 and 111 to 78.6, respectively, from January 2015 to December 2022, whereas that of ramelteon/ORAs increased from 7.41 to 54.4. In the LP-rate of BZDs and z-drugs, although the level significantly increased by factors of 1.08 [95% confidence interval (CI): 1.02-1.13] and 1.12 [95% CI: 1.08-1.16], respectively, at the intervention time, the slope change significantly decreased after the intervention (0.990 [95% CI: 0.988-0.992] and 0.994 [95% CI: 0.993-0.996]). In ramelteon/ORAs, the slope change with the increasing trend was significantly attenuated after the intervention (0.991 [95% CI: 0.986-0.995]).
CONCLUSIONS: The medical fee revisions related to polypharmacy significantly redirected the long-term prescription trends of BZDs, z-drugs, and ramelteon/ORAs toward a decline.